Acrivon Therapeutics clinical trials we track

Check company identity source

Phase 2 1 trial

TrialDrugs studiedStatusPrimary completion
A Phase 2 Study of ACR-368 in Endometrial AdenocarcinomaNCT05548296ACR-368, Gemcitabine, OncoSignatureRecruiting2027-05-30Estimated

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Arm 1: Anti-tumor activity of ACR-368 in Endometrial cancer subjects that are OncoSignature Positive. Measure: Arm 2: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects that are OncoSignature Negative. Measure: Arm 3: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (All-Comers).. After: Measure: Arm 1: Anti-tumor activity of ACR-368 in Endometrial cancer subjects that are OncoSignature Positive. Measure: Arm 2: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects that are OncoSignature Negative. Measure: Arm 3: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (Serous All-Comers). Measure: Arm 4: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (Serous All-Comers)..

Planned enrollment increased by 48 participants

Before: 353 participants (planned). After: 401 participants (planned).

Primary completion date changed

Before: 31 Oct 2026. After: 30 May 2027.

Check registry source